Long-term study of zasocitinib for joint and skin psoriatic arthritis
Checks long-term safety of zasocitinib in adults with active psoriatic arthritis.
Plain-language title generated from the registry record
Registry title: Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Key facts
- Where
- Chuo-ku, Fukuoka, Meguro-ku, Meguro-Ku, Minami-ku, Nagoya-shi, Mitaka-shi, Nagoya, Osaka, Sasebo-Shi, Sendai, and Tsu, Mie, JapanSee the 11 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with psoriatic arthritis who finished the 52-week treatment period in one of two earlier zasocitinib studies. All take zasocitinib once a day.
- Age
- 18 years or older (19 years or older in South Korea).
- Sex
- All sexes can join.
- Disease stage
- Psoriatic arthritis, in people whose doctor thinks they can benefit from zasocitinib.
- Earlier treatment
- Must have completed the 52-week treatment period in study TAK-279-PsA-3001 or TAK-279-PsA-3002, without having to stop the treatment permanently.
Main reasons for not taking part
- The doctor thinks the person did not benefit from the treatment in the earlier study.
- Met the criteria for permanent stop of treatment in the earlier study.
- Developed another disease that could confuse the results, such as rheumatoid arthritis, lupus, gout or fibromyalgia.
- Developed a skin condition that could interfere with the study assessments.
Read by machine on 12 November 2026.
Where in Japan
- St. Luke's International HospitalChuo-ku, JapanContact: Satoshi Kawaai (principal investigator)Taking people
- Fukuoka University HospitalFukuoka, JapanContact: Shinichi Imafuku (principal investigator)Taking people
- Toho University Ohashi Medical CenterMeguro-ku, JapanContact: Hideto Kameda (principal investigator)Taking people
- National Hospital Organization Tokyo Medical CenterMeguro-Ku, JapanContact: Katsuya Suzuki (principal investigator)Taking people
- Kojunkai Social Medical Corporation Daido ClinicMinami-ku, Nagoya-shi, JapanContact: Yoichiro Haji (principal investigator)Taking people
- Kyorin University HospitalMitaka-shi, JapanContact: Mitsumasa Kishimoto (principal investigator)Taking people
- Nagoya City University HospitalNagoya, JapanContact: Akimichi Morita (principal investigator)Taking people
- Nippon Life HospitalOsaka, JapanContact: Shigeyoshi Tsuji (principal investigator)Taking people
- Sasebo Chuo HospitalSasebo-Shi, JapanContact: Yukitaka Ueki (principal investigator)Taking people
- Tohoku University HospitalSendai, JapanContact: Hiroshi Fujii (principal investigator)Taking people
- Mie University HospitalTsu, Mie, JapanContact: Keiichi Yamanaka (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Takeda
- Trial code
- NCT07286058EU 2025-522586-30-00
- Record updated
- 12 November 2026
- Original description
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.Read full original descriptionShow less
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.
The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.
Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 [NCT06671483] or TAK-279-PsA-3002 [NCT06671496]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).
Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
Inclusion: The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age; The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies; The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy.
Exclusion: The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO); The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia; Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study; Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002).